The Prognostic Value of Survivin Expression in Patients with Colorectal Carcinoma: A Meta-analysis

The prognostic role of survivin in colorectal carcinoma remains controversial. This meta-analysis aimed to explore the association between survivin expression and survival outcomes in patients with colorectal carcinoma. A comprehensive literature search for relevant studies published up to April 2013 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which survivin was detected by immunohistochemical staining were included. This meta-analysis was done using STATA and Review Manager. A total of 1784 patients from 14 studies were included in the analysis. Our results showed that survivin overexpression in patients with colorectal carcinoma was significantly associated with poor overall survival (hazard ratio, 1.505; 95 confidence interval, 1.1971.893; P 0.000) and disease-free survival (hazard ratio, 2.323; 95 confidence interval, 1.6873.199; P 0.000). The results indicated that a significant relationship between survivin expression and overall survival was also exhibited in studies with an Asian country (hazard ratio, 1.684; 95 confidence interval, 1.4771.921), patient number 100 (hazard ratio, 1.604; 95 confidence interval, 1.3711.877), the cut-off level 50 (hazard ratio, 1.449; 95 confidence interval, 1.0452.010), the percentage of survivin overexpression 50 (hazard ratio, 1.528; 95 confidence interval, 1.0562.211) and the hazard ratio estimated (hazard ratio, 1.643; 95 confidence interval, 1.2622.139). Moreover, upregulation of survivin was associated with stages (III/IV vs. I/II: odds ratio, 1.08; 95 confidence interval, 0.801.46), the depth of invasion (T3/T4 vs. T1/T2: odds ratio, 1.79; 95 confidence interval 0.674.74), lymph node metastasis (positive vs. negative: odds ratio, 1.49; 95 confidence interval, 0.992.26), distant metastasis (positive vs. negative: odds ratio, 2.37; 95 confidence interval, 0.995.72) and grade of differentiation (well/moderate vs. poor: odds ratio, 1.02; 95 confidence interval, 0.432.41), but without significance. The present meta-analysis indicated that upregulation of survivin was associated with poor prognosis in patients with colorectal carcinoma.